Mirum Pharmaceuticals - MIRM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $49.73
  • Forecasted Upside: 102.89%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$24.51
▼ -0.96 (-3.77%)

This chart shows the closing price for MIRM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mirum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MIRM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MIRM

Analyst Price Target is $49.73
▲ +102.89% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $49.73, with a high forecast of $66.00 and a low forecast of $37.00. The average price target represents a 102.89% upside from the last price of $24.51.

This chart shows the closing price for MIRM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Mirum Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2022
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2023
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2023
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2023
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2023
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2024

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024Morgan StanleyLower TargetOverweight ➝ Overweight$57.00 ➝ $53.00Low
5/9/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$72.00 ➝ $66.00Low
5/9/2024CitigroupBoost TargetBuy ➝ Buy$37.00 ➝ $38.00Low
5/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$40.00Low
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$58.00Low
4/17/2024Stifel NicolausInitiated CoverageBuy$48.00Low
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$58.00Low
3/18/2024SVB LeerinkLower TargetOutperform ➝ Outperform$44.00 ➝ $43.00Low
3/14/2024HC WainwrightBoost TargetBuy ➝ Buy$45.00 ➝ $58.00Low
3/14/2024JMP SecuritiesBoost TargetOutperform ➝ Outperform$69.00 ➝ $72.00N/A
2/29/2024HC WainwrightLower TargetBuy ➝ Buy$58.00 ➝ $45.00Low
2/29/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$35.00Low
2/29/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$64.00 ➝ $69.00Low
1/11/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$64.00Low
12/19/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$78.00 ➝ $64.00Low
12/18/2023HC WainwrightLower TargetBuy ➝ Buy$60.00 ➝ $58.00Low
11/27/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
11/20/2023JPMorgan Chase & Co.Reiterated RatingOverweight$37.00Low
11/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
11/13/2023Morgan StanleyInitiated CoverageOverweight$60.00Low
11/3/2023HC WainwrightLower TargetBuy ➝ Buy$63.00 ➝ $60.00N/A
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$50.00Low
10/18/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$84.00 ➝ $77.00Low
10/18/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$70.00Low
10/17/2023Evercore ISIReiterated RatingOutperform$62.00Low
10/9/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$70.00Low
10/3/2023Robert W. BairdBoost Target$35.00 ➝ $38.00Low
9/20/2023JMP SecuritiesInitiated CoverageOutperform$70.00Low
9/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$63.00Low
8/21/2023Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$79.00 ➝ $84.00Low
8/4/2023HC WainwrightReiterated RatingBuy$63.00Low
8/4/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$82.00 ➝ $79.00Low
7/18/2023HC WainwrightBoost TargetBuy$61.00 ➝ $63.00Low
4/13/2023Raymond JamesLower TargetStrong-Buy$83.00 ➝ $81.00Low
4/6/2023HC WainwrightReiterated RatingBuy$61.00N/A
3/15/2023HC WainwrightReiterated RatingBuy$61.00Low
3/9/2023Raymond JamesLower TargetStrong-Buy$84.00 ➝ $83.00Low
3/9/2023HC WainwrightReiterated RatingBuy$61.00Low
2/15/2023HC WainwrightLower TargetBuy$69.00 ➝ $61.00Low
1/10/2023SVB LeerinkLower TargetOutperform$50.00 ➝ $39.00Low
1/10/2023Raymond JamesLower TargetStrong-Buy$88.00 ➝ $84.00Low
12/14/2022SVB LeerinkBoost TargetOutperform$49.00 ➝ $50.00Low
11/28/2022JPMorgan Chase & Co.Lower Target$30.00Low
11/14/2022HC WainwrightBoost TargetBuy$68.00 ➝ $69.00Low
11/10/2022CitigroupLower TargetBuy$38.00 ➝ $34.00Low
10/25/2022Raymond JamesBoost TargetStrong-Buy$75.00 ➝ $88.00Low
10/25/2022HC WainwrightBoost TargetBuy$63.00 ➝ $68.00Low
9/1/2022CitigroupInitiated CoverageBuy$38.00Low
8/11/2022HC WainwrightLower TargetBuy$69.00 ➝ $63.00Low
5/24/2022SVB LeerinkBoost TargetOutperform$50.00 ➝ $52.00Low
5/23/2022HC WainwrightBoost TargetBuy$64.00 ➝ $69.00Medium
4/26/2022SVB LeerinkBoost TargetOutperform$46.00 ➝ $49.00Medium
3/11/2022Raymond JamesBoost TargetStrong-Buy$70.00 ➝ $74.00Low
1/28/2022SVB LeerinkBoost TargetOutperform$42.00 ➝ $46.00Medium
1/12/2022Raymond JamesBoost TargetStrong-Buy$69.00 ➝ $70.00Medium
9/30/2021HC WainwrightBoost TargetAverage ➝ Buy$51.00 ➝ $64.00Low
9/30/2021SVB LeerinkBoost TargetOutperform$32.00 ➝ $41.00High
9/30/2021Raymond JamesBoost TargetBuy ➝ Strong-Buy$51.00 ➝ $69.00High
9/30/2021Robert W. BairdBoost TargetPositive ➝ Outperform$30.00 ➝ $34.00High
9/20/2021JPMorgan Chase & Co.Initiated CoverageOverweight$30.00High
9/14/2021HC WainwrightLower TargetBuy$52.00 ➝ $51.00High
9/14/2021Raymond JamesLower TargetStrong-Buy$52.00 ➝ $51.00High
9/13/2021SVB LeerinkLower TargetOutperform$33.00 ➝ $32.00High
8/6/2021HC WainwrightReiterated RatingBuyLow
8/6/2021SVB LeerinkLower TargetOutperform$38.00 ➝ $33.00High
7/27/2021HC WainwrightReiterated RatingBuy$15.24High
4/1/2021Robert W. BairdReiterated RatingBuy$30.00Medium
2/8/2021SVB LeerinkInitiated CoverageOutperform$38.00High
11/13/2020Raymond JamesBoost TargetStrong-Buy$48.00 ➝ $52.00High
9/9/2020GuggenheimBoost TargetBuy$27.00 ➝ $38.00High
9/3/2020HC WainwrightReiterated RatingBuy$52.00High
9/1/2020CitigroupBoost TargetBuy$28.00 ➝ $31.00High
8/7/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$28.00 ➝ $48.00High
8/3/2020HC WainwrightInitiated CoverageBuy$52.00Medium
7/30/2020Piper SandlerInitiated CoverageOverweightHigh
6/24/2020Robert W. BairdInitiated CoverageOutperform$30.00Low
5/8/2020Raymond JamesReiterated RatingOutperform$30.00 ➝ $28.00Low
12/17/2019CitigroupBoost TargetBuy$21.00 ➝ $30.00Medium
8/12/2019Roth CapitalInitiated CoverageBuy ➝ Buy$33.00High
8/12/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$28.00High
8/12/2019CitigroupInitiated CoverageBuy ➝ Buy$21.00High
8/12/2019GuggenheimInitiated CoverageBuy ➝ Buy$18.00High
8/12/2019Evercore ISIInitiated CoverageOutperform ➝ Outperform$25.00High
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/27/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
12/26/2023
  • 12 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 19 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/24/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/24/2024

Current Sentiment

  • 7 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Mirum Pharmaceuticals logo
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $24.51
Low: $24.48
High: $25.47

50 Day Range

MA: $25.25
Low: $23.57
High: $27.01

52 Week Range

Now: $24.51
Low: $23.14
High: $35.56

Volume

120,233 shs

Average Volume

523,413 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Mirum Pharmaceuticals?

The following sell-side analysts have issued research reports on Mirum Pharmaceuticals in the last year: Cantor Fitzgerald, Citigroup Inc., Evercore ISI, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Robert W. Baird, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for MIRM.

What is the current price target for Mirum Pharmaceuticals?

11 Wall Street analysts have set twelve-month price targets for Mirum Pharmaceuticals in the last year. Their average twelve-month price target is $49.73, suggesting a possible upside of 102.9%. JMP Securities has the highest price target set, predicting MIRM will reach $66.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $37.00 for Mirum Pharmaceuticals in the next year.
View the latest price targets for MIRM.

What is the current consensus analyst rating for Mirum Pharmaceuticals?

Mirum Pharmaceuticals currently has 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MIRM will outperform the market and that investors should add to their positions of Mirum Pharmaceuticals.
View the latest ratings for MIRM.

What other companies compete with Mirum Pharmaceuticals?

How do I contact Mirum Pharmaceuticals' investor relations team?

Mirum Pharmaceuticals' physical mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company's listed phone number is (650) 667-4085 and its investor relations email address is [email protected]. The official website for Mirum Pharmaceuticals is mirumpharma.com. Learn More about contacing Mirum Pharmaceuticals investor relations.